| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/5000 | Human,Mouse,Rat |
| Aliases | SP-D, PSP-D, SFTP4, COLEC7 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human SFTPD |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于SFTPD(肺表面活性蛋白D)抗体的研究文献摘要简述：
1. **文献名称**: *"Surfactant Protein D in Respiratory and Non-Respiratory Diseases"*
**作者**: Sorensen GL et al.
**摘要**: 该综述探讨了SFTPD在肺部疾病(如COPD、ARDS)和全身性疾病(如糖尿病、类风湿关节炎)中的免疫调节作用，并讨论了针对SFTPD的单克隆抗体在疾病诊断和机制研究中的应用潜力。
2. **文献名称**: *"Antibody recognition of pulmonary surfactant protein D defines a distinct molecular defect in rheumatoid arthritis"*
**作者**: Guo Y et al.
**摘要**: 研究发现类风湿关节炎患者血清中存在针对SFTPD的自身抗体，通过ELISA和免疫印迹技术证实其与疾病活动度相关，提示SFTPD抗体可能参与自身免疫反应的病理过程。
3. **文献名称**: *"Surfactant Protein D as a Biomarker for COVID-19 Severity"*
**作者**: Wu Y et al.
**摘要**: 该研究利用抗SFTPD抗体检测COVID-19患者血清和肺泡灌洗液中SFTPD水平，发现其浓度与肺损伤严重程度呈正相关，表明SFTPD可能作为评估病毒感染预后的生物标志物。
注：以上文献信息为示例性概括，具体内容需参考真实发表的论文(可通过PubMed或Google Scholar搜索标题获取原文)。
Surfactant protein D (SFTPD) is a member of the collectin family, primarily synthesized in pulmonary alveolar type II cells and non-ciliated bronchial epithelial cells. It plays a critical role in innate immunity by binding to pathogens, allergens, and apoptotic cells via its carbohydrate recognition domain (CRD), facilitating their clearance through opsonization or aggregation. SFTPD also modulates inflammatory responses by interacting with immune cell receptors, such as calreticulin/CD91. Structurally, it forms multimeric complexes through collagen-like regions, enhancing its functional efficiency.
Antibodies targeting SFTPD are essential tools in studying its biological roles and disease associations. Monoclonal and polyclonal anti-SFTPD antibodies are widely used in immunoassays (e.g., ELISA, Western blot, immunohistochemistry) to quantify protein levels or localize expression in tissues. Dysregulated SFTPD expression or autoantibodies against SFTPD have been implicated in respiratory diseases (e.g., COPD, idiopathic pulmonary fibrosis, ARDS) and autoimmune conditions. Research also explores SFTPD's dual role in infection defense versus potential contribution to chronic inflammation.
Clinically, anti-SFTPD antibodies may serve as biomarkers for disease progression or therapeutic targets. Recent studies investigate engineered antibodies to modulate SFTPD activity in inflammatory disorders. However, challenges remain in understanding isoform-specific functions and reconciling contradictory roles in different pathologies.
×
